Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)  is one of the most promising stocks with huge upside potential. On November 24, Barclays raised the firm’s price target on Syndax to $35 from $22, while maintaining an Overweight rating on the shares. The firm’s sentiment followed an overall update on the company’s model after speaking with management. Earlier the same month, Syndax Pharmaceuticals also released its Q3 2025 earnings report, where the company disclosed that it achieved total revenue of $45.9 milli ...